Compare CIK & INO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CIK | INO |
|---|---|---|
| Founded | N/A | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 127.8M | 118.9M |
| IPO Year | 1995 | 1999 |
| Metric | CIK | INO |
|---|---|---|
| Price | $2.34 | $1.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $5.33 |
| AVG Volume (30 Days) | 419.3K | ★ 14.3M |
| Earning Date | 01-01-0001 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.18 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $42,220,086.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 19.37 |
| 52 Week Low | $2.26 | $0.56 |
| 52 Week High | $2.88 | $2.72 |
| Indicator | CIK | INO |
|---|---|---|
| Relative Strength Index (RSI) | 62.48 | 62.51 |
| Support Level | $2.26 | $1.08 |
| Resistance Level | $2.40 | $1.85 |
| Average True Range (ATR) | 0.03 | 0.20 |
| MACD | 0.01 | 0.09 |
| Stochastic Oscillator | 91.67 | 64.88 |
Credit Suisse Asset Mgmt Income Fund Inc is a closed-end management investment company. The investment objective of the fund is to provide current income consistent with the preservation of capital. UBS Asset Management serves as an investment adviser for the fund. Asset Management offers a wide range of investment products and functions across asset classes and investment styles. The division manages various regional portfolios, mutual funds, and other investment vehicles for governments, institutions, corporations and individuals.
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.